Evidence map›Paper›PMID 37298528›Full record

ArticleInternational journal of molecular sciences2023

The 3q Oncogene

Julia C Radosa, Mariz Kasoha, Merle Doerk, Annika Cullmann, Askin C Kaya, Maximilian Linxweiler, Marc P Radosa, Zoltan Takacs, Andrea Tirincsi, Sven Lang and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Julia C RadosaDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Mariz KasohaDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.ORCID 0000-0002-5468-4597
Merle DoerkDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Annika CullmannDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Askin C KayaDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Maximilian LinxweilerDepartment of Otorhinolaryngology, Head and Neck Surgery, Saarland University Hospital, D-66421 Homburg, Germany.ORCID 0000-0002-5028-9282
Marc P RadosaDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Zoltan TakacsDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Andrea TirincsiMedical Biochemistry and Molecular Biology, Saarland University, D-66421 Homburg, Germany.
Sven LangMedical Biochemistry and Molecular Biology, Saarland University, D-66421 Homburg, Germany.
Martin JungMedical Biochemistry and Molecular Biology, Saarland University, D-66421 Homburg, Germany.ORCID 0000-0002-1482-7020
Julian PuppeDepartment of Gynecology, University Hospital Cologne, D-50931 Cologne, Germany.ORCID 0000-0001-6005-9491
Barbara LinxweilerDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Mathias WagnerDepartment of Pathology, Saarland University Hospital, D-66421 Homburg, Germany.
Rainer M BohleDepartment of Pathology, Saarland University Hospital, D-66421 Homburg, Germany.
Erich-Franz SolomayerDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.
Julia S M ZimmermannDepartment of Gynecology, Obstetrics and Reproductive Medicine, Saarland University Hospital, D-66421 Homburg, Germany.ORCID 0000-0003-0741-8664
Saarland University · DEKlinikum Bremen-Mitte · DEUniversity Hospital Cologne · DE

Funding

JSMZ was supported by HOMFOR (Homburger Forschungsförderungsprogramm, Saarland University, Homburg, Germany; grant number: T201000878). T201000878
6 · The paper itself

Abstract

In the absence of targeted treatment options, neoadjuvant chemotherapy (NACT) is applied widely for triple-negative breast cancer (TNBC). Response to NACT is an important parameter predictive of oncological outcomes (progression-free and overall survival). An approach to the evaluation of predictive markers enabling therapy individualization is the identification of tumor driver genetic mutations. This study was conducted to investigate the role of

Indexed as

Triple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsCell MovementHumansMembrane Transport ProteinsNeoadjuvant TherapyOncogenesMembrane Transport ProteinsSEC62 protein, humanneoadjuvant chemotherapyoncogene SEC62translational researchtriple-negative breast cancertumor cell migrationtumor pathogenesis

Identifiers

PMID37298528
PMCPMC10253301
OpenAlexW4379056687

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.